Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2028 By Drug Class, Application and Geography | The Insight Partners

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists); Application (Hospital, Clinics, Others) and Geography

Report Code: TIPRE00016876 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET INTRODUCTION

Human Immunodeficiency Virus (HIV)-1 Therapeutics are the drugs which are used in treatment of HIV. HIV is the infection of virus that affects body cells which help in fighting against infections and makes body more vulnerable to other opportunistic infections. Various drug therapeutic class available for treatment of human immunodeficiency virus.

MARKET DYNAMICS

The key market drivers for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Includes, extensive R&D activities by pharmaceutical companies to develop novel therapies, rising transmission rate of infection globally along with lack of awareness about HIV infection in developing countries are some of the factors which are expected to drive market growth during forecast period. Whereas, high cost of treatment, stringent regulatory approvals for drug therapy may restrain market growth during forecast period. s

MARKET SCOPE

The "Human Immunodeficiency Virus (HIV)-1 Therapeutics Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Human Immunodeficiency Virus (HIV)-1 Therapeutics market with detailed market segmentation by drug class and application. The Human Immunodeficiency Virus (HIV)-1 Therapeutics Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Human Immunodeficiency Virus (HIV)-1 Therapeutics Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Human Immunodeficiency Virus (HIV)-1 Therapeutics Market is segmented on the basis of drug class and application. On the basis of drug class the market is segmented into, NRTIS, NNRTIS, entry and fusion inhibitors, protease inhibitors, integrase inhibitors. And on the basis of application the market is segmented into, hospital, clinic and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Human Immunodeficiency Virus (HIV)-1 Therapeutics Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Human Immunodeficiency Virus (HIV)-1 Therapeutics Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Human Immunodeficiency Virus (HIV)-1 Therapeutics Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Human Immunodeficiency Virus (HIV)-1 Therapeutics Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Human Immunodeficiency Virus (HIV)-1 Therapeutics Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Human Immunodeficiency Virus (HIV)-1 Therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Human Immunodeficiency Virus (HIV)-1 Therapeutics Market.

The report also includes the profiles of key players in Human Immunodeficiency Virus (HIV)-1 Therapeutics Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •   Gilead Sciences,Inc
  •   Merck and Co, Inc
  •   Viiv Healthcare
  •   AbbVie ,Inc
  •   Bristol- Myers Squibb Company
  •   Boehringer Ingelheim GmbH
  •   Genentech,Inc
  •   Cipla,Inc
  •   Janssen Pharmaceutica
  •   Johnson and Johnson

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market - By Drug Class
1.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market - By Application
1.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. NUCLEOSIDE-ANALOG REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
7.3.1. Overview
7.3.2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Market Forecast and Analysis
7.4. NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
7.4.1. Overview
7.4.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Forecast and Analysis
7.5. ENTRY AND FUSION INHIBITORS
7.5.1. Overview
7.5.2. Entry and Fusion Inhibitors Market Forecast and Analysis
7.6. PROTEASE INHIBITORS (PIS)
7.6.1. Overview
7.6.2. Protease Inhibitors (PIs) Market Forecast and Analysis
7.7. INTEGRASE INHIBITORS
7.7.1. Overview
7.7.2. Integrase Inhibitors Market Forecast and Analysis
7.8. CORECEPTOR ANTAGONISTS
7.8.1. Overview
7.8.2. Coreceptor Antagonists Market Forecast and Analysis
8. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. CLINICS
8.4.1. Overview
8.4.2. Clinics Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. others Market Forecast and Analysis

9. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
9.1.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis
9.1.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Drug Class
9.1.4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Application
9.1.5 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.1.5.1.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.1.5.1.2 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.1.5.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.1.5.2.1 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.1.5.2.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.1.5.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.1.5.3.1 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.1.5.3.2 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2. EUROPE
9.2.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
9.2.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis
9.2.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Application
9.2.5 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.1.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.1.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2.5.2 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.2.1 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.2.2 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2.5.3 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.3.1 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.3.2 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2.5.4 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.4.1 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.4.2 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2.5.5 United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.5.1 United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.5.2 United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.2.5.6 Rest of Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.2.5.6.1 Rest of Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.2.5.6.2 Rest of Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
9.3.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.1.1 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.1.2 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3.5.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.2.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.2.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3.5.3 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.3.1 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.3.2 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3.5.4 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.4.1 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.4.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3.5.5 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.5.1 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.5.2 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.3.5.6 Rest of Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.3.5.6.1 Rest of Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
9.4.2 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.4.5.1.1 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.4.5.1.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.4.5.2 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.4.5.2.1 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.4.5.2.2 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.4.5.3 U.A.E Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.4.5.3.1 U.A.E Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.4.5.3.2 U.A.E Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.4.5.4 Rest of Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.4.5.4.1 Rest of Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
9.5.2 South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Application
9.5.5 South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.5.5.1.1 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.5.5.1.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.5.5.2 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.5.5.2.1 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.5.5.2.2 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
9.5.5.3 Rest of South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
9.5.5.3.1 Rest of South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Drug Class
9.5.5.3.2 Rest of South and Central America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. GILEAD SCIENCES, INC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. VIIV HEALTHCARE
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ABBVIE, INC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. MERCK AND CO., INC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BOEHRINGER INGELHEIM GMBH
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GENENTECH, INC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. CIPLA,INC
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. JANSSEN PHARMACEUTICA
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. JOHNSON AND JOHNSON
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Gilead Sciences, Inc
2. ViiV Healthcare
3. AbbVie, Inc
4. Merck and Co., Inc
5. Bristol-Myers Squibb Company
6. Boehringer Ingelheim GmbH
7. Genentech, Inc
8. Cipla,Inc
9. janssen Pharmaceutica
10. Johnson and Johnson
TIPRE00016876
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
    GET FREE SAMPLE PDF

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount